Drugs /
agen1181
Back to Drugs List
Associated Genetic Biomarkers
Overview
NCI Definition [1]:
An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody AGEN1181 binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody.
Clinical Trials
Agen1181 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating agen1181, 1 is phase 1/phase 2 (1 open).
Malignant solid tumor is the most common disease being investigated in agen1181 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
